Table 4.
Characteristics | Yes | n | Total, N | P | aOR | (95% CI) |
---|---|---|---|---|---|---|
Abscess | ||||||
Gender | ||||||
Male | 52% | 41 | 79 | |||
Female | 30% | 10 | 33 | 0·036 | † | |
Age (years) | ||||||
<25 | 0% | 0 | 5 | |||
25–29 | 30% | 9 | 30 | |||
30–34 | 48% | 15 | 31 | |||
⩾35 | 57% | 27 | 47 | 0·019 | † | |
Years since first injected | ||||||
<5 | 17% | 2 | 12 | 1·00 | ||
5–9 | 43% | 13 | 30 | 7·15 | (1·04–48·9) | |
10–14 | 39% | 13 | 33 | 5·01 | (0·75–33·4) | |
⩾15 | 59% | 23 | 39 | 0·059 | 25·9 | (3·54–189) |
Injected crack preceding year | ||||||
No | 21% | 7 | 33 | 1·00 | ||
Yes | 55% | 44 | 80 | 0·001 | 7·49 | (2·50–22·5) |
Shared N/S preceding year | ||||||
No | 40% | 34 | 85 | 1·00 | ||
Yes | 63% | 17 | 27 | <0·001 | 3·57 | (1·25–10·2) |
Anti-HBc test result | ||||||
Positive | 61% | 19 | 31 | |||
Negative | 39% | 31 | 80 | 0·032 | † | |
Anti-HCV test result | ||||||
Positive | 52% | 42 | 81 | |||
Negative | 29% | 9 | 31 | 0·030 | † | |
Redness, swelling and tenderness | ||||||
Gender | ||||||
Male | 34% | 36 | 105 | |||
Female | 21% | 11 | 53 | 0·079 | † | |
Age (years) | ||||||
<25 | 6·3% | 1 | 16 | |||
25–29 | 37% | 18 | 49 | |||
30–34 | 24% | 10 | 42 | |||
⩾35 | 35% | 18 | 51 | 0·077 | † | |
Injected crack preceding year | ||||||
No | 20% | 9 | 45 | |||
Yes | 34% | 39 | 114 | 0·079 | † | |
Imprisonment | ||||||
Never | 13% | 4 | 31 | |||
Yes, not preceding year | 33% | 29 | 89 | |||
Yes, preceding year | 38% | 15 | 39 | 0·052 | † | |
Anti-HBc test result | ||||||
Positive | 43% | 20 | 47 | |||
Negative | 24% | 27 | 112 | 0·020 | † | |
Anti-HCV test result | ||||||
Positive | 37% | 37 | 101 | 1·00 | ||
Negative | 18% | 10 | 57 | 0·012 | 0·38 | (0·17–0·83) |
aOR, Adjusted odds ratio; CI, confidence interval; N/S, needles or syringe.
Not included in the final model.